ESANO ACA
Our product is sourced from C-Section donors from Tissue Banks with Tissue Reference Group (TRG) Certification and in accordance with FDA regulations under 21 CFR Part 1271 ensuring blood testing resulting in clearance of any HIV, HBsAg, HBc Total, HCV, and RPRcomorbidities. The HCT/Ps are processed in accordance with FDA's Good Tissue Practice regulations in a controlled cleanroom environment and sterilized using electron-beam irradiation to meet the Sterility Assurance Level.
ESANO ACA is a triple layer, Amnion Chorion Amnion graft which enables Omnidirectional/Side Agnostic usage.
The graft is dehydrated removing the usage of any solution or refrigeration and allowing a 5 year Shelf Life at room temperature storage.
BENEFITS AND USAGE OF ESANO ACA
Contains cytokines - epidermal, keratinocyte, hepatocyte, and Fibroblast growth factors Is non-immunogenic, has anti-inflammatory effect and significantly reduces wound desiccation .Our graft can be used from Stages 2 through 4 except in cases where the wound has any underlying infection or has not completed 30 days of prior conventional therapy which did not result in more than 50% shrinkage in wound dimensions.
PATIENTS WHO BENEFIT:
DIABETICS WITH REDUCED SENSATION OR POOR ,CIRCULATION
POOR CIRCULATION IN FEET AND LEGS (PAD} WITHOUT DIABETES
PATIENTS WITH RAYNAUD'S DISEASE WITH FOOT/TOE INVOLVEMENT
PATIENTS WITH RHEUMATOID ARTHRITIS, LUPUS, SCLERODERMA
PATIENTS WITH VENOUS INSUFFICIENCY WHO DEVELOP SWELLING IN LEG/FEET
DIALYSIS AND TRASPLANT PATIENTS
PATIENTS WITH NEUROPATHY AND WEAKENED IMMUNE SYSTEM
THE TYPES OF CHRONIC WOUNDS APPROVED FOR USAGE ARE:
DIABETIC FOOT ULCERS (DFUS), VENOUS LEG ULCERS (VLUS),
PRESSURE/SACRAL WOUNDS, LACERATIONS/BURN INJURIES
BEFORE
AFTER
After six applications
BEFORE
AFTER
